U.S. Markets open in 40 mins
  • S&P Futures

    3,323.75
    -59.25 (-1.75%)
     
  • Dow Futures

    26,811.00
    -554.00 (-2.02%)
     
  • Nasdaq Futures

    11,412.00
    -176.00 (-1.52%)
     
  • Russell 2000 Futures

    1,554.80
    -34.20 (-2.15%)
     
  • Crude Oil

    37.75
    -1.82 (-4.60%)
     
  • Gold

    1,878.80
    -33.10 (-1.73%)
     
  • Silver

    23.69
    -0.88 (-3.58%)
     
  • EUR/USD

    1.1725
    -0.0065 (-0.5511%)
     
  • 10-Yr Bond

    0.7530
    -0.0250 (-3.21%)
     
  • Vix

    37.05
    +4.59 (+14.14%)
     
  • GBP/USD

    1.2924
    -0.0117 (-0.8995%)
     
  • USD/JPY

    104.4300
    -0.0640 (-0.0613%)
     
  • BTC-USD

    13,237.12
    -472.89 (-3.45%)
     
  • CMC Crypto 200

    261.74
    +0.45 (+0.17%)
     
  • FTSE 100

    5,618.19
    -110.80 (-1.93%)
     
  • Nikkei 225

    23,418.51
    -75.79 (-0.32%)
     

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of BioMarin Pharmaceutical Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 24, 2020 - BMRN

Newsfile Corp.
·2 mins read

New York, New York--(Newsfile Corp. - September 29, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of BioMarin Pharmaceutical Inc. ("BioMarin") (NASDAQ: BMRN) between February 28, 2020 and August 18, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the the United States District Court for the Northern District of California. To get more information go to:

https://www.zlk.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form?prid=9675&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec, an investigational adenoassociated virus gene therapy, limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec's durability of effect; (ii) as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

If you suffered a loss in BioMarin you have until November 24, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64893